References

1. 1..
   Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
2. 2..
   Jiang X, Liu G, Li Y, Pan Y. Immune checkpoint: the novel target for antitumor therapy. Genes Dis. 2021;8(1):25–37.
3. 3..
   Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019;30(10):1653–9.
4. 4..
   Peters S, Kerr KM, Stahel R. PD-1 blockade in advanced NSCLC: a focus on pembrolizumab. Cancer Treat Rev. 2018;62:39–49.
5. 5..
   Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer. 2015;3:36.
6. 6..
   Chen Y, Wang L, Zheng M, Zhu C, Wang G, Xia Y, et al. Engineered extracellular vesicles for concurrent anti-PDL1 immunotherapy and chemotherapy. Bioact Mater. 2022;9:251–65.
7. 7..
   Deng R, Bumbaca D, Pastuskovas CV, Boswell CA, West D, Cowan KJ, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs. 2016;8(3):593–603.
8. 8..
   Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics. 2019;13:33–51.
9. 9..
   Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, et al. Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy. Drug Des Devel Ther. 2020;14:3625–49.
10. 10..
    Xiao WY, Wang Y, An HW, Hou D, Mamuti M, Wang MD, et al. Click reaction-assisted peptide immune checkpoint blockade for solid tumor treatment. ACS Appl Mater Interfaces. 2020;12(36):40042–51.
11. 11..
    Alimohammadi R, Alibeigi R, Nikpoor AR, Chalbatani GM, Webster TJ, Jaafari MR, et al. Encapsulated checkpoint blocker before chemotherapy: the optimal sequence of anti-CTLA-4 and doxil combination therapy. Int J Nanomedicine. 2020;15:5279–88.
12. 12..
    Deveuve Q, Lajoie L, Barrault B, Thibault G. The proteolytic cleavage of therapeutic monoclonal antibody hinge region: more than a matter of subclass. Front Immunol. 2020;11:168.
13. 13..
    Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125–8.
14. 14..
    Morgado M, Placido A, Morgado S, Roque F. Management of the adverse effects of immune checkpoint inhibitors. Vaccines (Basel). 2020;8(4):575.
15. 15..
    Kahler KC, Hassel JC, Heinzerling L, Loquai C, Thoms KM, Ugurel S, et al. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma—an update. J Dtsch Dermatol Ges. 2020;18(6):582–609.
16. 16..
    Calvo R. Hematological side effects of immune checkpoint inhibitors: the example of immune-related thrombocytopenia. Front Pharmacol. 2019;10:454.
17. 17..
    Lombardi A, Mondelli MU. Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. Aliment Pharmacol Ther. 2019;50(8):872–84.
18. 18..
    Barrueto L, Caminero F, Cash L, Makris C, Lamichhane P, Deshmukh RR. Resistance to checkpoint inhibition in cancer immunotherapy. Transl Oncol. 2020;13(3):100738.
19. 19..
    Russell BL, Sooklal SA, Malindisa ST, Daka LJ, Ntwasa M. The tumor microenvironment factors that promote resistance to immune checkpoint blockade therapy. Front Oncol. 2021;11:641428.
20. 20..
    Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol. 2016;28(8):383–91.
21. 21..
    Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(4):12.
22. 22..
    Lamichhane N, Udayakumar TS, D’souza WD, Simone CB 2nd, Raghavan SR, Polf J, et al. Liposomes: clinical applications and potential for imageguided drug delivery. Molecules. 2018;23(2):288.
23. 23..
    Lu Y, Gao Y, Yang H, Hu Y, Li X. Nanomedicine-boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma. Mil Med Res. 2022;9(1):69.
24. 24..
    Guimaraes D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021;601:120571.
25. 25..
    López-Camacho A, Higuera-Ciapara I, Velázquez-Fernández JB, Beltrán-Gracia E, Vallejo-Cardona AA. Nanomedicine review: clinical developments in liposomal applications. Cancer Nanotechnol. 2019;10(1):1–40.
26. 26..
    Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
27. 27..
    Barenholz Y. Doxil®–the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–34.
28. 28..
    Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4(3):e10143.
29. 29..
    Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1):271–84.
30. 30..
    Allen TM, Hansen CB, de Menezes DEL. Pharmacokinetics of longcirculating liposomes. Adv Drug Deliver Rev. 1995;16(2):267–84.
31. 31..
    Kobayashi H, Watanabe R, Choyke PL. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?. Theranostics. 2013;4(1):81–9.
32. 32..
    Wu J. The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Pers Med. 2021;11(8):771.
33. 33..
    Thakkar S, Sharma D, Kalia K, Tekade RK. Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: a review. Acta Biomater. 2020;101:43–68.
34. 34..
    Wei X, Chen X, Ying M, Lu W. Brain tumor-targeted drug delivery strategies. Acta Pharm Sin B. 2014;4(3):193–201.
35. 35..
    Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumortargeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71(3):409–19.
36. 36..
    Large DE, Soucy JR, Hebert J, Auguste DT. Advances in receptor-mediated, tumor-targeted drug delivery. Adv Therap. 2019;2:1800091.
37. 37..
    Gullotti E, Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm. 2009;6(4):1041–51.
38. 38..
    Qin SY, Zhang AQ, Zhang XZ. Recent advances in targeted tumor chemotherapy based on smart nanomedicines. Small. 2018;14(45):e1802417.
39. 39..
    He Q, Chen J, Yan J, Cai S, Xiong H, Liu Y, et al. Tumor microenvironment responsive drug delivery systems. Asian J Pharm Sci. 2020;15(4):416–48.
40. 40..
    Guo X, Cheng Y, Zhao X, Luo Y, Chen J, Yuan WE. Advances in redox-responsive drug delivery systems of tumor microenvironment. J Nanobiotechnology. 2018;16(1):74.
41. 41..
    Jia R, Teng L, Gao L, Su T, Fu L, Qiu Z, et al. Advances in multiple stimuli-responsive drug-delivery systems for cancer therapy. Int J Nanomedicine. 2021;16:1525–51.
42. 42..
    Shein SA, Kuznetsov II, Abakumova TO, Chelushkin PS, Melnikov PA, Korchagina AA, et al. VEGF- and VEGFR2-targeted liposomes for cisplatin delivery to glioma cells. Mol Pharm. 2016;13(11):3712–23.
43. 43..
    Zhou Q, Shao S, Wang J, Xu C, Xiang J, Piao Y, et al. Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy. Nat Nanotechnol. 2019;14(8):799–809.
44. 44..
    Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–94.
45. 45..
    Man F, Gawne PJ, de Rosales RTM. Nuclear imaging of liposomal drug delivery systems: a critical review of radiolabelling methods and applications in nanomedicine. Adv Drug Deliv Rev. 2019;143:134–60.
46. 46..
    Kim EM, Jeong HJ. Liposomes: biomedical applications. Chonnam Med J. 2021;57(1):27–35.
47. 47..
    Cheng X, Gao J, Ding Y, Lu Y, Wei Q, Cui D, et al. Multi-functional liposome: a powerful theranostic nano-platform enhancing photodynamic therapy. Adv Sci (Weinh). 2021;8(16):e2100876.
48. 48..
    Xia Y, Xu C, Zhang X, Ning P, Wang Z, Tian J, et al. Liposome-based probes for molecular imaging: from basic research to the bedside. Nanoscale. 2019;11(13):5822–38.
49. 49..
    Gu ZL, Da Silva CG, Van Der Maaden K, Ossendorp F, Cruz LJ. Liposome-based drug delivery systems in cancer immunotherapy. Pharmaceutics. 2020;12(11):1054.
50. 50..
    Xing C, Li H, Li RJ, Yin L, Zhang HF, Huang ZN, et al. The roles of exosomal immune checkpoint proteins in tumors. Mil Med Res. 2021;8(1):56.
51. 51..
    Ou W, Jiang L, Gu Y, Soe ZC, Kim BK, Gautam M, et al. Regulatory T cells tailored with pH-responsive liposomes shape an immunoantitumor milieu against tumors. ACS Appl Mater Interfaces. 2019;11(40):36333–46.
52. 52..
    Merino M, Contreras A, Casares N, Troconiz IF, Ten Hagen TL, Berraondo P, et al. A new immune-nanoplatform for promoting adaptive antitumor immune response. Nanomedicine. 2019;17:13–25.
53. 53..
    Li YJ, Wu JY, Hu XB, Ding T, Tang T, Xiang DX. Biomimetic liposome with surface-bound elastase for enhanced tumor penetration and chemoimmumotherapy. Adv Healthc Mater. 2021;10(19):e2100794.
54. 54..
    Zhao H, Zhao B, Wu L, Xiao H, Ding K, Zheng C, et al. Amplified cancer immunotherapy of a surface-engineered antigenic microparticle vaccine by synergistically modulating tumor microenvironment. ACS Nano. 2019;13(11):12553–66.
55. 55..
    Li C, Qiu Q, Gao X, Yan X, Fan C, Luo X, et al. Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy. J Control Release. 2021;337:393–406.
56. 56..
    Huang TY, Huang GL, Zhang CY, Zhuang BW, Liu BX, Su LY, et al. Supramolecular photothermal nanomedicine mediated distant tumor inhibition via PD-1 and TIM-3 blockage. Front Chem. 2020;8:1.
57. 57..
    Cremolini C, Vitale E, Rastaldo R, Giachino C. Advanced nanotechnology for enhancing immune checkpoint blockade therapy. Nanomaterials (Basel). 2021;11(3):661.
58. 58..
    Lahori DG, Varamini P. Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy. Future Oncol. 2021;17(6):711–22.
59. 59..
    Phung CD, Pham TT, Nguyen HT, Nguyen TT, Ou W, Jeong JH, et al. Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses. Acta Biomater. 2020;115:371–82.
60. 60..
    Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers. 2021;13(6):1440.
61. 61..
    Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers. 2020;12(3):738.
62. 62..
    Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai C, et al. Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res. 2019;29(8):609–27.
63. 63..
    Nikpoor AR, Tavakkol-Afshari J, Sadri K, Jalali SA, Jaafari MR. Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: in vitro and in vivo studies. Nanomedicine. 2017;13(8):2671–82.
64. 64..
    Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153–67.
65. 65..
    Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–87.
66. 66..
    Wu Y, Chen W, Xu ZP, Gu W. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. 2019;10:2022.
67. 67..
    Merino M, Lozano T, Casares N, Lana H, Troconiz IF, Ten Hagen TLM, et al. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. J Nanobiotechnology. 2021;19(1):102.
68. 68..
    He ZD, Zhang M, Wang YH, He Y, Wang HR, Chen BF, et al. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy. Acta Pharmacol Sin. 2021;42(9):1516–23.
69. 69..
    Serrano-Del Valle A, Anel A, Naval J, Marzo I. Immunogenic cell death and immunotherapy of multiple myeloma. Front Cell Dev Biol. 2019;7:50.
70. 70..
    Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. Immunogenic cell death in cancer therapy: present and emerging inducers. J Cell Mol Med. 2019;23(8):4854–65.
71. 71..
    Jiang G, Deng W, Liu Y, Wang C. General mechanism of JQ1 in inhibiting various types of cancer. Mol Med Rep. 2020;21(3):1021–34.
72. 72..
    Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549(7670):101–5.
73. 73..
    Yang S, Shim MK, Song S, Cho H, Choi J, Jeon SI, et al. Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity. Biomaterials. 2022;290:121841.
74. 74..
    Huang L, Li Y, Du Y, Zhang Y, Wang X, Ding Y, et al. Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy. Nat Commun. 2019;10(1):4871.
75. 75..
    Ma G, Kostevsek N, Monaco I, Ruiz A, Markelc B, Cheung CCL, et al. PD1 blockade potentiates the therapeutic efficacy of photothermally-activated and MRI-guided low temperature-sensitive magnetoliposomes. J Control Release. 2021;332:419–33.
76. 76..
    Yu J, He X, Wang Z, Wang Y, Liu S, Li X, et al. Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumorspecific immunological response. Nanoscale. 2021;13(30):12966–78.
77. 77..
    Li Y, Teng X, Wang Y, Yang C, Yan X, Li J. Neutrophil delivered hollow titania covered persistent luminescent nanosensitizer for ultrosound augmented chemo/immuno glioblastoma therapy. Adv Sci. 2021;8(17):2004381.
78. 78..
    Lin B, Chen H, Liang D, Lin W, Qi X, Liu H, et al. Acidic pH and high-H₂O₂ dual tumor microenvironment-responsive nanocatalytic graphene oxide for cancer selective therapy and recognition. ACS Appl Mater Interfaces. 2019;11(12):11157–66.
79. 79..
    Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer. Annu Rev Physiol. 2020;82:103–26.
80. 80..
    Feng L, Dong Z, Tao D, Zhang Y, Liu Z. The acidic tumor microenvironment: a target for smart cancer nano-theranostics. Natl Sci Rev. 2018;5(2):269–86.
81. 81..
    Gu Z, Wang Q, Shi Y, Huang Y, Zhang J, Zhang X, et al. Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity. J Control Release. 2018;286:369–80.
82. 82..
    Banstola A, Poudel K, Pathak S, Shrestha P, Kim JO, Jeong JH, et al. Hypoxia-mediated ROS amplification triggers mitochondria-mediated apoptotic cell death via PD-L1/ROS-responsive, dual-targeted, drug-laden thioketal nanoparticles. ACS Appl Mater Interfaces. 2021;13(19):22955–69.
83. 83..
    Daund V, Chalke S, Sherje AP, Kale PP. ROS responsive mesoporous silica nanoparticles for smart drug delivery: a review. J Drug Deliver Sci Technol. 2021;64:102599.
84. 84..
    Li Y, Chen M, Yao B, Lu X, Song B, Vasilatos SN, et al. Dual pH/ROS-responsive nanoplatform with deep tumor penetration and self-amplified drug release for enhancing tumor chemotherapeutic efficacy. Small. 2020;16(32):e2002188.
85. 85..
    Wang Y, Yu J, Li D, Zhao L, Sun B, Wang J, et al. Paclitaxel derivative-based liposomal nanoplatform for potentiated chemo-immunotherapy. J Control Release. 2022;341:812–27.
86. 86..
    Brown GT, Murray GI. Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 2015;237(3):273–81.
87. 87..
    Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 1999;189(3):300–8.
88. 88..
    Isaacson KJ, Martin Jensen M, Subrahmanyam NB, Ghandehari H. Matrix-metalloproteinases as targets for controlled delivery in cancer: an analysis of upregulation and expression. J Control Release. 2017;259:62–75.
89. 89..
    Zhang M, Fang Z, Zhang H, Cui M, Wang M, Liu K. Reversing tumor immunosuppressive microenvironment via targeting codelivery of CpG ODNs/PD-L1 peptide antagonists to enhance the immune checkpoint blockade-based anti-tumor effect. Eur J Pharm Sci. 2022;168:106044.
90. 90..
    Lang T, Liu Y, Zheng Z, Ran W, Zhai Y, Yin Q, et al. Cocktail strategy based on spatio-temporally controlled nano device improves therapy of breast cancer. Adv Mater. 2019;31(5):1806202.
91. 91..
    Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124–34.
92. 92..
    Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol. 2012;44(12):2144–51.
93. 93..
    Lu S, Yang N, He J, Gong W, Lai Z, Xie L, et al. Generation of cancer-specific cytotoxic PD-1-T cells using liposome-encapsulated CRISPR/Cas system with dendritic/tumor fusion cells. J Biomed Nanotechnol. 2019;15(3):593–601.
94. 94..
    Lian S, Xie R, Ye Y, Xie X, Li S, Lu Y, et al. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. EBioMedicine. 2019;42:281–95.
95. 95..
    Barati M, Mirzavi F, Nikpoor AR, Sankian M, Namdar Ahmadabad H, Soleimani A, et al. Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes. Cancer Gene Ther. 2021;29(6):814–24.
96. 96..
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
97. 97..
    Liao Q, Zhou Y, Xia L, Cao D. Lipid metabolism and immune checkpoints. Adv Exp Med Biol. 2021;1316:191–211.
98. 98..
    Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–9.
99. 99..
    Boone CE, Wang L, Gautam A, Newton IG, Steinmetz NF. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022;14(1):e1739.
100. 100..
     Guo M, Han S, Liu Y, Guo W, Zhao Y, Liu F, et al. Inhibition of allogeneic islet graft rejection by VISTA-conjugated liposome. Biochem Biophys Res Commun. 2019;516(3):914–20.
101. 101..
     Torphy R, Schulick R, Zhu Y. Newly emerging immune checkpoints: promises for future cancer therapy. Int J Mol Sci. 2017;18(12):2642.
102. 102..
     Chen YL, Lin HW, Chien CL, Lai YL, Sun WZ, Chen CA, et al. BTLA blockade enhances cancer therapy by inhibiting IL-6/IL-10-induced CD19-high B lymphocytes. J Immunother Cancer. 2019;7(1):313.
103. 103..
     Chen S, Wainwright DA, Wu JD, Wan Y, Matei DE, Zhang Y, et al. CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy. 2019;11(11):983–97.
104. 104..
     Zhou W, Guo S, Liu M, Burow ME, Wang G. Targeting CXCL12/CXCR4 axis in tumor immunotherapy. Cur Med Chem. 2019;26(17):3026–41.
105. 105..
     Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene. 2016;35(7):816–26.
106. 106..
     Shi Y, Riese DJ 2nd, Shen J. The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer. Front Pharmacol. 2020;11:574667.
107. 107..
     Lu G, Qiu Y, Su X. Targeting CXCL12-CXCR4 signaling enhances immune checkpoint blockade therapy against triple negative breast cancer. Eur J Pharm Sci. 2021;157:105606.
108. 108..
     Hornyak L, Dobos N, Koncz G, Karanyi Z, Pall D, Szabo Z, et al. The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. Front Immunol. 2018;9:151.
109. 109..
     Pallotta MT, Rossini S, Suvieri C, Coletti A, Orabona C, Macchiarulo A, et al. Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme. FEBS J. 2022;289(20):6099–118.
110. 110..
     Tang K, Wu YH, Song Y, Yu B. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. J Hematol Oncol. 2021;14(1):68.
111. 111..
     Huang Z, Wei G, Zeng Z, Huang Y, Huang L, Shen Y, et al. Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor. Theranostics. 2019;9(19):5542–57.
112. 112..
     Liu D, Chen B, Mo Y, Wang Z, Qi T, Zhang Q, et al. Redox-activated porphyrin-based liposome remote-loaded with indoleamine 2,3-dioxygenase (IDO) inhibitor for synergistic photoimmunotherapy through induction of immunogenic cell death and blockage of IDO pathway. Nano Lett. 2019;19(10):6964–76.
113. 113..
     Cheng L, Hill AF. Therapeutically harnessing extracellular vesicles. Nat Rev Drug Discov. 2022;21(5):379–99.
114. 114..
     Antimisiaris SG, Mourtas S, Marazioti A. Exosomes and exosome-inspired vesicles for targeted drug delivery. Pharmaceutics. 2018;10(4):218.
115. 115..
     Ozverel CS. Exosome mimetic nanovesicles; are they next best alternative therapeutic approach combating cancer?. Cyprus J Med Sci. 2020;5(4):361–4.
116. 116..
     Lu M, Huang YY. Bioinspired exosome-like therapeutics and delivery nanoplatforms. Biomaterials. 2020;242:23.
117. 117..
     Kenific CM, Zhang H, Lyden D. An exosome pathway without an ESCRT. Cell Res. 2021;31(2):105–6.
118. 118..
     Chen L, Wang L, Zhu L, Xu Z, Liu Y, Li Z, et al. Exosomes as drug carriers in anti-cancer therapy. Front Cell Dev Biol. 2022;10:728616.
119. 119..
     Chinnappan M, Srivastava A, Amreddy N, Razaq M, Pareek V, Ahmed R, et al. Exosomes as drug delivery vehicle and contributor of resistance to anticancer drugs. Cancer Lett. 2020;486:18–28.
120. 120..
     Zhao Y, Liu L, Sun R, Cui G, Guo S, Han S, et al. Exosomes in cancer immunoediting and immunotherapy. Asian J Pharm Sci. 2022;17(2):193–205.
121. 121..
     Zhou K, Guo S, Li F, Sun Q, Liang G. Exosomal PD-L1: new insights into tumor immune escape mechanisms and therapeutic strategies. Front Cell Dev Biol. 2020;8:569219.
122. 122..
     Chen H, Wang L, Zeng X, Schwarz H, Nanda HS, Peng X, et al. Exosomes, a new star for targeted delivery. Front Cell Dev Biol. 2021;9:751079.
123. 123..
     Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16(7):748–59.
124. 124..
     Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11(7):3183–95.
125. 125..
     Fan Y, Zhou Y, Lu M, Si H, Li L, Tang B. Responsive dual-targeting exosome as a drug carrier for combination cancer immunotherapy. Research (Wash D C). 2021;2021:9862876.
126. 126..
     Pei X, Zhang X, Zhang L, Yuan M, Sun L, Yu F, et al. Targeted exosomes for co-delivery of siFGL1 and siTGF-β1 trigger combined cancer immunotherapy by remodeling immunosuppressive tumor microenvironment. Chem Eng J. 2021;421:129774.
127. 127..
     Severic M, Ma G, Pereira SGT, Ruiz A, Cheung CCL, Al-Jamal WT. Genetically-engineered anti-PSMA exosome mimetics targeting advanced prostate cancer in vitro and in vivo. J Control Release. 2020;330:101–10.
128. 128..
     Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013;19(20):5626–35.
129. 129..
     Zhou Q, Ding W, Qian Z, Zhu Q, Sun C, Yu Q, et al. Immunotherapy strategy targeting programmed cell death ligand 1 and CD73 with macrophage-derived mimetic nanovesicles to treat bladder cancer. Mol Pharm. 2021;18(11):4015–28.
130. 130..
     Zhang X, Wang J, Chen Z, Hu Q, Wang C, Yan J, et al. Engineering PD-1-presenting platelets for cancer immunotherapy. Nano Lett. 2018;18(9):5716–25.
131. 131..
     Centanni M, Moes D, Troconiz IF, Ciccolini J, Van Hasselt JGC. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019;58(7):835–57.
132. 132..
     Feng Y, Masson E, Dai D, Parker SM, Berman D, Roy A. Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br J Clin Pharmacol. 2014;78(1):106–17.
133. 133..
     O’brien T, Dolan L. Immune checkpoint inhibitors and timing of administration. Lancet Oncol. 2022;23(2):e55.
134. 134..
     Shinno Y, Goto Y, Ohuchi M, Hamada A, Nokihara H, Fujiwara Y, et al. The long half-life of programmed cell death protein 1 inhibitors may increase the frequency of immune-related adverse events after subsequent EGFR tyrosine kinase inhibitor therapy. JTO Clin Res Rep. 2020;1(1):100008.
135. 135..
     Lin W, Kampf N, Goldberg R, Driver MJ, Klein J. Poly-phosphocholinated liposomes form stable superlubrication vectors. Langmuir. 2019;35(18):6048–54.
136. 136..
     He H, Liu L, Morin EE, Liu M, Schwendeman A. Survey of clinical translation of cancer nanomedicines-lessons learned from successes and failures. Acc Chem Res. 2019;52(9):2445–61.
137. 137..
     Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014.
138. 138..
     De Lázaro I, Mooney DJ. A nanoparticle’s pathway into tumours. Nat Mater. 2020;19(5):486–7.
139. 139..
     Challenging paradigms in tumour drug delivery. Nat Mater. 2020;19(5):477.
140. 140..
     Sainaga Jyothi VGS, Bulusu R, Rao BVK, Pranothi M, Banda S, Kumar Bolla P, et al. Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: an update. Int J Pharm. 2022;624:122022.
141. 141..
     Nakhaei P, Margiana R, Bokov DO, Abdelbasset WK, Jadidi Kouhbanani MA, Varma RS, et al. Liposomes: structure, biomedical applications, and stability parameters with emphasis on cholesterol. Front Bioeng Biotechnol. 2021;9:705886.